Short Interest in HCW Biologics Inc. (NASDAQ:HCWB) Grows By 212.2%

HCW Biologics Inc. (NASDAQ:HCWB) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 12,800 shares, a growth of 212.2% from the August 31st total of 4,100 shares. Based on an average trading volume of 24,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.1% of the shares of the stock are sold short.

HCW Biologics Price Performance

Shares of HCW Biologics stock traded down $0.03 during trading on Friday, reaching $0.51. 981 shares of the company’s stock were exchanged, compared to its average volume of 18,266. The firm’s 50-day moving average price is $0.55 and its 200 day moving average price is $0.98. The company has a market cap of $19.34 million, a P/E ratio of -0.67 and a beta of 0.78. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.10 and a current ratio of 0.10. HCW Biologics has a 1-year low of $0.40 and a 1-year high of $2.14.

HCW Biologics (NASDAQ:HCWB) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter. HCW Biologics had a negative net margin of 978.03% and a negative return on equity of 385.90%. The company had revenue of $0.62 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HCW Biologics stock. Pullen Investment Management LLC acquired a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 85,116 shares of the company’s stock, valued at approximately $149,000. Pullen Investment Management LLC owned about 0.23% of HCW Biologics at the end of the most recent reporting period. Institutional investors own 2.96% of the company’s stock.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.